Elias Nabbout
Internal Medicine · Tewksbury, MANPI 1366416265
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,387 and has fallen 97.0% since, to $101 in 2024. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$591
- Novo Nordisk$303
- Merck$291
- AbbVie$274
- Takeda Pharmaceuticals U.S.A., Inc.$237
- Astellas Pharma US Inc$235
- plus $2K from 18 others
What the payments were for
- Food & beverage$3,52997%
- Education$1053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 44 | $591 |
| Novo Nordisk | 22 | $303 |
| Merck | 19 | $291 |
| AbbVie(2 entities) | 26 | $274 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $237 |
| Astellas Pharma US Inc | 6 | $235 |
| Johnson & Johnson | 14 | $228 |
| Teva Pharmaceuticals USA, Inc. | 45 | $197 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $189 |
| Amgen(2 entities) | 10 | $186 |
| GSK | 12 | $178 |
| Novartis | 9 | $165 |
| Lilly USA, LLC | 10 | $142 |
| Sanofi-aventis U.S. LLC | 7 | $123 |
| Boehringer Ingelheim | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Scilex Pharmaceuticals Inc. | 3 | $45 |
| Amarin Pharma, Inc. | 1 | $23 |
| Gilead | 1 | $22 |
| Shire North American Group Inc | 1 | $18 |
| Abbott | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$125
- TRINTELLIX$108
How this compares
$3,634 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Tewksbury
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.